Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Contributed by: Business Wire

Logo

Tags

Medical Supplies

Health

Infectious Diseases

Other Health

Pharmaceutical

Biotechnology

Biological E. Limited

More Like This

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

PR Newswire associated0

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

PR Newswire associated0

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

PR Newswire associated0

Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions